Association Between Socioeconomic Status, Sex, and Age at Death from Cystic Fibrosis in England and Wales (1959 to 2008): Cross Sectional Study

Overview

Journal BMJ

Specialty General Medicine

Date 2011 Aug 25

PMID 21862532

Citations 33

Authors

Helen L Barr

John Britton

Alan R Smyth

Andrew W Fogarty

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the trend in the association between socioeconomic status and sex and median age at death from cystic fibrosis in England and Wales, over the past 50 years.

Design: Series of annual cross sectional studies of all registered deaths with a diagnosis of cystic fibrosis in England and Wales, from 1959 to 2008.

Methods: We obtained national mortality data for cystic fibrosis from the Office for National Statistics. From 1959 to 2000, the Registrar General's Social Class coded socioeconomic status as manual or non-manual. From 2001 onwards, the National Statistics Socioeconomic Classification was implemented and socioeconomic status was split into three groups: professional and managerial, intermediate, and routine and manual. We calculated median age at death for every study year. We calculated the effects of sex and socioeconomic status on the odds of death above the median age at death for every study decade using logistic regression.

Results: From 1959 to 2008, 6750 deaths were attributed to cystic fibrosis in England and Wales. Males were more likely to die above the annual median age at death than females (from 1959 to 1999, adjusted odds ratio for socioeconomic status 1.28, 95% confidence intervals 1.13 to 1.45; from 2000 to 2008, 1.57, 1.18 to 2.08). Individuals in the highest socioeconomic class were also more likely to die above the median age of death than those in the lowest socioeconomic class (from 1959 to 2000, adjusted odds ratio for sex 2.50, 2.16 to 2.90; from 2001 to 2008, 1.89, 1.20 to 2.97).

Conclusions: Socioeconomic status and sex remain strong determinants of survival from cystic fibrosis in England and Wales, and the magnitude of these effects does not appear to have substantially reduced over time.

Citing Articles

How Do Early Weight Trajectories Explain Social Inequalities in Lung Function in Children With Cystic Fibrosis?: A Longitudinal Interventional Disparity Effects Analysis With Time-varying Mediators and Intermediate Confounders.

Schluter D, Keogh R, Daniel R, Agbla S, Taylor-Robinson D Epidemiology. 2025; 36(2):275-285.

PMID: 39760864 PMC: 11774196. DOI: 10.1097/EDE.0000000000001826.

Aiming to Improve Equity in Pulmonary Health: Cystic Fibrosis.

Oates G, Schechter M Clin Chest Med. 2023; 44(3):555-573.

PMID: 37517835 PMC: 10458995. DOI: 10.1016/j.ccm.2023.03.011.

Trends in inequality in maternal and child health and health care in Uganda: Analysis of the Uganda demographic and health surveys.

Kakama A, Basaza R BMC Health Serv Res. 2022; 22(1):1269.

PMID: 36266643 PMC: 9585693. DOI: 10.1186/s12913-022-08630-x.

Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Oates G, Schechter M Expert Rev Respir Med. 2022; 16(6):637-650.

PMID: 35705523 PMC: 9329222. DOI: 10.1080/17476348.2022.2090928.

Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.

McGarry M, Gibb E, Oates G, Schechter M Paediatr Respir Rev. 2022; 42:35-42.

PMID: 35277357 PMC: 9356388. DOI: 10.1016/j.prrv.2021.12.001.

References

Borowitz D, Robinson K, Rosenfeld M, Davis S, Sabadosa K, Spear S . Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009; 155(6 Suppl):S73-93. PMC: 6324931. DOI: 10.1016/j.jpeds.2009.09.001. View

Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R . Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34(2):91-100. DOI: 10.1002/ppul.10127. View

Schechter M, Margolis P . Relationship between socioeconomic status and disease severity in cystic fibrosis. J Pediatr. 1998; 132(2):260-4. DOI: 10.1016/s0022-3476(98)70442-1. View

Armstrong D, Bell S, Robinson M, Bye P, Rose B, Harbour C . Evidence for spread of a clonal strain of Pseudomonas aeruginosa among cystic fibrosis clinics. J Clin Microbiol. 2003; 41(5):2266-7. PMC: 154738. DOI: 10.1128/JCM.41.5.2266-2267.2003. View

OConnor G, Quinton H, Kneeland T, Kahn R, Lever T, Maddock J . Median household income and mortality rate in cystic fibrosis. Pediatrics. 2003; 111(4 Pt 1):e333-9. DOI: 10.1542/peds.111.4.e333. View

Corey M, Edwards L, Levison H, Knowles M . Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr. 1998; 131(6):809-14. DOI: 10.1016/s0022-3476(97)70025-8. View

Elborn J, Hodson M, Bertram C . Implementation of European standards of care for cystic fibrosis - provision of care. J Cyst Fibros. 2009; 8(5):348-55. DOI: 10.1016/j.jcf.2009.05.004. View

Huang N, Schidlow D, Szatrowski T, Palmer J, Yeung W, Hardy K . Clinical features, survival rate, and prognostic factors in young adults with cystic fibrosis. Am J Med. 1987; 82(5):871-9. DOI: 10.1016/0002-9343(87)90147-1. View

Selvadurai H, Blimkie C, Cooper P, Mellis C, Van Asperen P . Gender differences in habitual activity in children with cystic fibrosis. Arch Dis Child. 2004; 89(10):928-33. PMC: 1719659. DOI: 10.1136/adc.2003.034249. View

10.

Johansen H, Nir M, Hoiby N, Koch C, Schwartz M . Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet. 1991; 337(8742):631-4. DOI: 10.1016/0140-6736(91)92449-c. View

11.

Schechter M, McColley S, Silva S, Haselkorn T, Konstan M, Wagener J . Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr. 2009; 155(5):634-9.e1-4. PMC: 4161122. DOI: 10.1016/j.jpeds.2009.04.059. View

12.

Arrington-Sanders R, Yi M, Tsevat J, Wilmott R, Mrus J, Britto M . Gender differences in health-related quality of life of adolescents with cystic fibrosis. Health Qual Life Outcomes. 2006; 4:5. PMC: 1402258. DOI: 10.1186/1477-7525-4-5. View

13.

Jackson A . Clinical guidelines for cystic fibrosis care. Summary of guidelines prepared by a working group of the Cystic Fibrosis Trust, the British Paediatric Association and the British Thoracic Society. J R Coll Physicians Lond. 1996; 30(4):305-8. PMC: 5401590. View

14.

FitzSimmons S . The changing epidemiology of cystic fibrosis. J Pediatr. 1993; 122(1):1-9. DOI: 10.1016/s0022-3476(05)83478-x. View

15.

Merelle M, Schouten J, Gerritsen J, Dankert-Roelse J . Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J. 2001; 18(2):306-15. DOI: 10.1183/09031936.01.00080101. View

16.

Penketh A, Wise A, MEARNS M, Hodson M, Batten J . Cystic fibrosis in adolescents and adults. Thorax. 1987; 42(7):526-32. PMC: 460820. DOI: 10.1136/thx.42.7.526. View

17.

Yankaskas J, Marshall B, Sufian B, Simon R, Rodman D . Cystic fibrosis adult care: consensus conference report. Chest. 2004; 125(1 Suppl):1S-39S. DOI: 10.1378/chest.125.1_suppl.1s. View

18.

Hill D, Martin A, Davidson G, Smith G . Survival of cystic fibrosis patients in South Australia. Evidence that cystic fibrosis centre care leads to better survival. Med J Aust. 1985; 143(6):230-2. DOI: 10.5694/j.1326-5377.1985.tb122953.x. View

19.

Farrell P, Lai H, Li Z, Kosorok M, Laxova A, Green C . Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough!. J Pediatr. 2005; 147(3 Suppl):S30-6. DOI: 10.1016/j.jpeds.2005.08.012. View

20.

Collins C, MacDonald-Wicks L, Rowe S, OLoughlin E, Henry R . Normal growth in cystic fibrosis associated with a specialised centre. Arch Dis Child. 1999; 81(3):241-6. PMC: 1718083. DOI: 10.1136/adc.81.3.241. View